The efficacy and safety of methotrexate versus interferon in cutaneous T-cell lymphomas

Abstract Objectives: Methotrexate (MTX) and interferon (IFN) have been used in the treatment of cutaneous T-cell lymphomas (CTCL) of various subtypes. We review our experience of MTX and IFN use in our patients with CTCL at a tertiary hospital. Materials and methods: Medical records of patients over 4 years were reviewed. We describe the dosages, time to response, response rates, side effects, progression rate, and reasons for discontinuation. Results: Response rate was significantly higher in the IFN group than MTX group (86.67% and 47.4% respectively, p = .01). Disease progression occurred 57.89% in the MTX group whilst only 26.67% progressed with IFN therapy. Patients taking IFN therapy experienced proportionally more side effects of any type than those undertaking MTX treatment (86.67% vs. 47.37%, odds ratio 7.22). However, discontinuation rate in the IFN group (26.67%) was much lower than in the MTX arm (89.47%). Conclusions: The most significant finding of this study was that patients with CTCL treated with IFN had a better response rate and significantly shorter response time compared with those treated with MTX. Additionally, patients had less disease progression on IFN than with MTX regardless of subtype of T-cell lymphoma and stage of disease.

[1]  C. Querfeld,et al.  Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome. , 2018, Cancer treatment and research.

[2]  A. Rook,et al.  The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. , 2015, Dermatologic clinics.

[3]  S. Horwitz,et al.  Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. , 2014, Journal of the American Academy of Dermatology.

[4]  H. Prince,et al.  Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies. , 2013, Clinical lymphoma, myeloma & leukemia.

[5]  T. Kuzel,et al.  Long‐term follow‐up and survival of cutaneous T‐cell lymphoma patients treated with extracorporeal photopheresis , 2012, Photodermatology, photoimmunology & photomedicine.

[6]  F. Foss.  Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma , 2011, Expert opinion on drug metabolism & toxicology.

[7]  C. Antoniou,et al.  PUVA plus interferon α2b in the treatment of advanced or refractory to PUVA early stage mycosis fungoides: a case series , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Olsen,et al.  Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. , 2009, Clinical lymphoma & myeloma.

[10]  J. Scarisbrick,et al.  Bexarotene therapy for mycosis fungoides and Sézary syndrome , 2009, The British journal of dermatology.

[11]  A. Fleischer,et al.  Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma , 2009, The Journal of dermatological treatment.

[12]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[13]  R. Dummer,et al.  The optimal use of bexarotene in cutaneous T‐cell lymphoma , 2007, The British journal of dermatology.

[14]  T. Kuzel,et al.  Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. , 2005, Archives of dermatology.

[15]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. , 2003, Journal of the American Academy of Dermatology.

[16]  H. Prince,et al.  Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab , 2003, European journal of haematology.

[17]  W. Sterry,et al.  Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. , 1998, Blood.

[18]  M. Kashani-Sabet,et al.  Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients. , 1996, Journal of the American Academy of Dermatology.

[19]  C. McDonald,et al.  Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue. , 1995, Archives of dermatology.

[20]  G. Vejlsgaard,et al.  Interferon treatment of cutaneous T‐cell lymphoma , 1993, European journal of haematology.

[21]  E. Olsen.  The pharmacology of methotrexate. , 1991, Journal of the American Academy of Dermatology.

[22]  R. Vollmer,et al.  Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. , 1989, Journal of the American Academy of Dermatology.

[23]  J. Bertino,et al.  Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. , 1978, Cancer treatment reports.

[24]  J. Q. Rosso,et al.  Bexarotene therapy for mycosis fungoides and Sézary syndrome , 2010 .

[25]  G. Burg,et al.  Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. , 2002, Journal of the American Academy of Dermatology.